NEW YORK (GenomeWeb News) - Biomax Informatics said this week that it has been selected as a consortium partner in Austria’s OncoTyrol project Center for Personalized Cancer Medicine.
The four-year, €28 million ($43.7 million) OncoTyrol initiative focuses on “translating genomic, proteomic and metabolomic research into innovative, individualized, and cost-effective approaches for cancer diagnosis and treatment,” Biomax said.
The company will provide its BioXM knowledge-management platform for the project.
"After an in-depth evaluation we concluded that the BioXM system, with its highly visual approach and outstanding data integration capabilities, is the backbone we need” for the project, Armin Graber, head of the institute for bioinformatics at the University for Health Sciences, Medical Informatics and Technology, and head of bioinformatics and system biology for the OncoTyrol initiative, said in a statement.
OncoTyrol comprises a consortium of researchers at the Biomedical Campus Innsbruck, the University Hospital Innsbruck, and other academic and industrial partners.